Skip to main content
. 2024 Nov 5;98(12):e01285-24. doi: 10.1128/jvi.01285-24

Fig 7.

Timeline of vaccination status, infection outcomes, immune responses, severity for different SARS-CoV-2 variants, and RNA-Seq analysis comparing unvaccinated and vaccinated groups. Reinfection risk depicted at 5 months post-infection.

Schematic representation of the effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk. (A) Representation of virus-specific immune effectors and the clinical severity during acute SARS-CoV-2 infection across vaccine doses. (B) The immune response and reinfection risk 5 months following initial COVID-19 development across vaccine dose groups. Created with Biorender.com.